Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.
Acurx Pharmaceuticals, Inc. develops small-molecule antibiotics for difficult-to-treat bacterial infections through a Gram-positive selective spectrum approach targeting DNA polymerase IIIC. Its pipeline includes ibezapolstat for Clostridioides difficile infection and additional DNA pol IIIC inhibitor candidates directed at Gram-positive pathogens such as MRSA, VRE, drug-resistant Streptococcus pneumoniae and B. anthracis.
Recurring ACXP news covers antibiotic development updates, microbiome data, scientific conference presentations, intellectual property for DNA pol IIIC inhibitors, financial results, registered offerings, warrant activity and investor-presentation announcements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) recently presented key findings at ECCMID 2023 in Copenhagen regarding its novel antibiotic ibezapolstat. Research showcased ibezapolstat’s unique action against C. difficile infections, demonstrating efficacy against resistant strains. The presentation highlighted positive outcomes from Phase 2a trials, where ibezapolstat achieved 100% clinical cure rates without recurrence. Additionally, updates on the company's preclinical antibiotic program targeting systemic gram-positive infections were provided. Ibezapolstat has already received FDA QIDP and Fast-Track Designation, indicating its potential as a significant treatment for bacterial infections. Acurx is currently enrolling patients for a Phase 2b clinical trial for C. difficile infection.
Acurx Pharmaceuticals announced the FDA's acceptance of its Interim Analysis Plan for an Independent Data Monitoring Committee (IDMC) to evaluate clinical outcomes in its Phase 2b clinical trial of ibezapolstat for treating Clostridioides difficile Infection (CDI) upon reaching 36 patient enrollments. This follows a successful Phase 2a trial, which demonstrated a 100% clinical cure rate. The Company will present findings at ECCMID 2023, including a poster on ibezapolstat's novel pharmacologic properties. The Phase 2b trial is a randomized, double-blind study comparing ibezapolstat to vancomycin, aiming to enroll 64 patients and assess anti-recurrence effects. Ibezapolstat has received QIDP and Fast Track designations from the FDA, highlighting its potential in an urgent therapeutic area. The Company also plans to share updates on its antibiotic pipeline at ECCMID.